CN110036015B - 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物 - Google Patents

可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物 Download PDF

Info

Publication number
CN110036015B
CN110036015B CN201780075174.6A CN201780075174A CN110036015B CN 110036015 B CN110036015 B CN 110036015B CN 201780075174 A CN201780075174 A CN 201780075174A CN 110036015 B CN110036015 B CN 110036015B
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
compound
pharmaceutically acceptable
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780075174.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110036015A (zh
Inventor
S·H·什派尔盖
M·E·默茨曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN110036015A publication Critical patent/CN110036015A/zh
Application granted granted Critical
Publication of CN110036015B publication Critical patent/CN110036015B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780075174.6A 2016-10-07 2017-10-02 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物 Active CN110036015B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405309P 2016-10-07 2016-10-07
US62/405,309 2016-10-07
PCT/US2017/054710 WO2018067432A1 (en) 2016-10-07 2017-10-02 Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses

Publications (2)

Publication Number Publication Date
CN110036015A CN110036015A (zh) 2019-07-19
CN110036015B true CN110036015B (zh) 2022-07-19

Family

ID=60117794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780075174.6A Active CN110036015B (zh) 2016-10-07 2017-10-02 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物

Country Status (8)

Country Link
US (1) US10836770B2 (cg-RX-API-DMAC7.html)
EP (1) EP3523305B1 (cg-RX-API-DMAC7.html)
JP (1) JP7097875B2 (cg-RX-API-DMAC7.html)
KR (1) KR102531036B1 (cg-RX-API-DMAC7.html)
CN (1) CN110036015B (cg-RX-API-DMAC7.html)
ES (1) ES2902995T3 (cg-RX-API-DMAC7.html)
MA (1) MA46453A (cg-RX-API-DMAC7.html)
WO (1) WO2018067432A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
KR102793119B1 (ko) * 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
BR112021008675A2 (pt) 2018-11-05 2021-08-10 Syngenta Participations Ag compostos de azole-amida pesticidamente ativos
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020182649A1 (en) 2019-03-08 2020-09-17 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
JP7549601B2 (ja) 2019-03-20 2024-09-11 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物活性アゾールアミド化合物
US20220213063A1 (en) 2019-03-22 2022-07-07 Syngenta Crop Protection Ag N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
CA3167313A1 (en) 2020-02-12 2021-08-19 Thomas John Bleisch Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN115916207A (zh) * 2020-08-20 2023-04-04 轶诺(浙江)药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN116655636A (zh) * 2022-02-17 2023-08-29 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981033A (zh) * 2008-02-06 2011-02-23 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN108473500A (zh) * 2015-11-18 2018-08-31 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981033A (zh) * 2008-02-06 2011-02-23 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
CN105992768A (zh) * 2013-12-10 2016-10-05 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CN108473500A (zh) * 2015-11-18 2018-08-31 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物

Also Published As

Publication number Publication date
JP7097875B2 (ja) 2022-07-08
US20190225620A1 (en) 2019-07-25
MA46453A (fr) 2019-08-14
CN110036015A (zh) 2019-07-19
ES2902995T3 (es) 2022-03-30
JP2019530699A (ja) 2019-10-24
WO2018067432A1 (en) 2018-04-12
US10836770B2 (en) 2020-11-17
KR20190057132A (ko) 2019-05-27
EP3523305A1 (en) 2019-08-14
EP3523305B1 (en) 2021-12-08
KR102531036B1 (ko) 2023-05-09

Similar Documents

Publication Publication Date Title
CN108473500B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
EP3523305B1 (en) Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
CN111936486B (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
TWI620737B (zh) 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
TWI582077B (zh) 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
CN105992768B (zh) 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物
CA3118094A1 (en) Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha
CN110191887B (zh) IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂
EP3917912B1 (en) Amide-disubstituted pyridine or pyridazine compounds
CN110114357B (zh) 可用作IL-12、IL-23和/或IFNα反应的调节剂的杂双环化合物
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
HK1226400B (en) Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant